CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer

Core Insights - CytoDyn Inc. has initiated patient enrollment for a clinical trial assessing the efficacy of leronlimab in relapsed/refractory microsatellite stable colorectal cancer [1][2] - The trial is being conducted in partnership with Syneos Health, involving multiple clinical sites [2] - Colorectal cancer is a significant global health issue, with approximately 1.9 million new cases and over 900,000 deaths annually [3] Company Overview - CytoDyn is a clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody targeting CCR5, with applications in oncology and other therapeutic areas [6] - The company aims to provide innovative treatment options for challenging diseases, as highlighted by the dosing of the first patient in the Phase II CRC trial [4] Clinical Trial Details - The trial is led by Dr. Ben Weinberg from Georgetown University and aims to evaluate the potential clinical benefits of leronlimab in colorectal cancer [2][5] - Previous studies have shown promising survival rates for leronlimab in metastatic triple-negative breast cancer, indicating its potential applicability across various solid tumors [5] Industry Context - The World Health Organization's IARC identifies colorectal cancer as the third most common cancer type and the second leading cause of cancer-related deaths globally [3] - The increasing incidence of colorectal cancer in individuals under 50 years old has been noted for over 20 years, indicating a growing public health concern [3]